Medicines labeled for the same conditions
Alternatives to insulin glargine and lixisenatide
13 other medicines are given the same way (subcutaneous) and in the same FDA class as insulin glargine and lixisenatide or labeled mainly for the same use (type 2 diabetes); 11 are in its class, GLP-1 receptor agonists: tirzepatide, liraglutide, insulin aspart, insulin lispro and 7 more; the others include 1 insulin and 1 amylin analog (FDA labels read October 8, 2026). In the same class, the lowest pharmacy cost is $6.95 per mL (Insulin aspart 100 unit/mL vial) (what pharmacies paid in the NADAC survey; strengths differ).
Which medicines are labeled for the same conditions as insulin glargine and lixisenatide?
Type 2 diabetes lists all 52 medicines labeled for it, by any route. Each row shows the conditions both labels name. They are listed as public records, not as substitutes: whether one can replace another depends on the person and is a prescriber's decision.
| Medicine and FDA class | Shared indication | Generic labelers (subcutaneous) | Pharmacy cost | Boxed warning | Shortage |
|---|---|---|---|---|---|
| Insulin glargine and lixisenatideGLP-1 receptor agonist | this medicine | none listed | $57.06 per mL 100 unit-33 mcg/mL pen | No | No current entry |
| Tirzepatideglucose-dependent insulinotropic polypeptide receptor agonist · same class | Type 2 diabetes | none listed | $538.68 per mL 10 mg/0.5 mL pen | Yes | No current entry |
| LiraglutideGLP-1 receptor agonist · same class | Type 2 diabetes | 9 labelers | $31.41 per mL 2-pak 18 mg/3 mL | Yes | In shortage |
| Insulin aspartinsulin analog · same class | Type 2 diabetes | none listed | $6.95 per mL 100 unit/mL vial | No | No current entry |
| Insulin lisproinsulin analog · same class | Type 2 diabetes | none listed | $10.19 per mL 100 unit/mL kwikpen | No | A presentation being discontinued |
| SemaglutideGLP-1 receptor agonist · same class | Type 2 diabetes | none listed | $331.99 per mL 0.25-0.5 mg/dose (2 mg/3 mL) pen | Yes | A presentation being discontinued |
| DulaglutideGLP-1 receptor agonist · same class | Type 2 diabetes | none listed | $487.57 per mL 0.75 mg/0.5 mL pen | Yes | No current entry |
| Insulin degludecinsulin analog · same class | Type 2 diabetes | none listed | $11.39 per mL 100 unit/mL pen | No | No current entry |
| ExenatideGLP-1 receptor agonist · same class | Type 2 diabetes | 1 labeler | $300.17 per mL 10 mcg dose pen injection | No | No current entry |
| Insulin degludec and liraglutideGLP-1 receptor agonist · same class | Type 2 diabetes | none listed | $85.89 per mL 100 unit-3.6 mg/mL pen | Yes | No current entry |
| Insulin detemirinsulin analog · same class | Type 2 diabetes | none listed | n/a | No | No current entry |
| Insulin glulisineinsulin analog · same class | Type 2 diabetes | none listed | $8.16 per mL 100 unit/mL vial | No | No current entry |
| Insulin humaninsulin | Type 2 diabetes | none listed | $4.26 per mL 70-30 vial | No | No current entry |
| Pramlintideamylin analog | Type 2 diabetes | none listed | n/a | Yes | A presentation being discontinued |
Source: FDA drug labels (indications) via openFDA; FDA NDC Directory; CMS NADAC of October 7, 2026; FDA Drug Shortage Database (FDA files October 8, 2026)
What do pharmacies pay for each?
The headline NADAC price per unit of each medicine's most widely listed form; strengths differ, so compare like with like on each record.
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
What next?
- Insulin glargine and lixisenatide: the full record
- label, generics, price, shortages, recalls